In this article, Sino Biological discusses emerging targets that are arising within the field of cancer immunotherapy, They also discuss the importance of cancer as a public health threat.
Patients with cancer are at an increased risk for SARS-CoV-2 infection and severe COVID-19 because of the lowered immunity associated with anticancer drugs, radiation therapy, and cancer itself, as well as increased exposure due to frequent visits to the hospital.
Roche reported that its drug tiragolumab failed to achieve one of two main goals of a Phase 3 study in non-small cell lung cancer. The antibody is designed to block TIGIT, a checkpoint protein that has been a hot target for pharmaceutical companies looking for a way to broaden the reach of cancer immunotherapy.